AstraZeneca Pharma India Ltd. (ASTRAZEN)

Overview

AstraZeneca Pharma India Limited is a prominent biopharmaceutical company that plays a significant role in the healthcare industry both in India and on a global scale. Specializing in the manufacture, distribution, and marketing of pharmaceutical products, the company has established a solid reputation for delivering high-quality medicines across various therapeutic areas. Incorporated in 1979 and headquartered in Bengaluru, India, AstraZeneca Pharma India Limited operates as a key subsidiary of AstraZeneca Pharmaceuticals AB, thereby benefiting from the vast R&D resources and global reach of its parent entity. Through its extensive product portfolio and ongoing commitment to innovation, the company meets the healthcare needs of patients with several medical conditions, advancing public health outcomes around the world.

Products and Services

• Cardiovascular, Renal, and Metabolism Medicines:

  Marketed under brand names such as CRESTOR for cholesterol management, Forxiga for diabetes and heart conditions, BRILINTA for preventing blood clots, Xigduo for diabetes treatment, and Seloken XL for hypertension and heart issues. These products focus on improving the lives of patients dealing with heart diseases, kidney issues, and metabolic disorders.

• Oncology Medicines:

  Offerings include TAGRISSO for non-small cell lung cancer, CALQUENCE for mantle cell lymphoma, Lynparza for ovarian and breast cancer, ENHERTU for HER2-positive breast cancer, IMFINZI for bladder cancer, and Zoladex for prostate and breast cancers. These oncology drugs represent breakthrough treatments that address a spectrum of cancers with precision medicine.

• Rare Diseases Medicines:

  AstraZeneca markets Koselugo for the treatment of children with neurofibromatosis type 1, a genetic condition that causes tumors to grow along nerves. This underscores the company’s dedication to tackling challenging rare diseases with innovative therapies.

• Respiratory Medicines:

  Products like Symbicort for asthma and COPD (Chronic Obstructive Pulmonary Disease) and Fasenra for severe eosinophilic asthma focus on improving respiratory health. AstraZeneca's respiratory medicines are designed to help patients breathe easier and live better lives with chronic lung conditions.

• Diabetes and Immunology:

  In addition to its portfolio, AstraZeneca is involved in developing and providing medicines aimed at treating diabetes and immunological disorders. These efforts are part of the company’s broader mission to address complex health challenges through innovative treatments.

• Clinical Trial Services:

  Beyond pharmaceutical manufacturing, AstraZeneca Pharma India Limited is engaged in offering clinical trial services. This service facilitates the development of new drugs and therapies, ensuring they are safe and effective for patient use before they are marketed. The company's comprehensive approach underscores its commitment to advancing medical science and improving patient care.